Eligibility Module
The Eligibility Module contains detailed information about who can participate in the clinical trial. This includes eligibility criteria, age restrictions, gender requirements, healthy volunteer status, and study population descriptions, helping researchers understand who is eligible to participate in the study.
Eligibility Module path is as follows:
Study -> Protocol Section -> Eligibility Module
Eligibility Module
Ignite Creation Date:
2025-12-25 @ 3:08 AM
Ignite Modification Date:
2025-12-25 @ 3:08 AM
NCT ID:
NCT03588533
Eligibility Criteria:
Inclusion Criteria:
1. Gastric or gastroesophageal junction adenocarcinoma
2. HER-2 immuno-histochemical (IHC) (3 +) stain or her-2 silver in situ hybridization(SISH)/fluorescence in situ hybridization(FISH) (+)
3. Herzuma® -capecitabine/cisplatin combination regimen is planned as a first line treatment
Exclusion Criteria:
1. Other type of cancer of Gastric or gastroesophageal junction adenocarcinoma (e.g., lymphoma, sarcoma)
2. HER-2 (0/1+) in IHC or her-2 SISH/FISH (-).
3. Patients who previously performed stomach cancer treatment as a palliative setting.
Healthy Volunteers:
False
Sex:
ALL
Minimum Age:
20 Years
Study:
NCT03588533
Study Brief:
Protocol Section:
NCT03588533